High affinity of ergopeptides for cytochromes P450 3A. Importance of their peptide moiety for P450 recognition and hydroxylation of bromocriptine.

The interaction between rat and human liver cytochromes P450 with a series of lysergic acid derivatives and ergopeptide alkaloids was studied by difference visible spectroscopy. Ergopeptides, like bromocriptine, ergocryptine and dihydroergotamine, strongly interacted with rat liver microsomes with the appearance of a difference spectrum which is characteristic of their binding to a protein site close to the heme. The intensity of this spectrum was clearly dependent on the amounts of P450s 3A in the microsomes and was at its maximum in dexamethasone-treated rat microsomes. All the ergopeptides studied exhibited a high affinity for rat P450s 3A (Ks around 1 microM), although lysergic acid derivatives not bearing the tripeptide moiety failed to give significant interactions with these P450s. A cyclic azatripeptide exhibiting a structure very similar to that of the tripeptide moiety of ergopeptides also interacted with P450s 3A with appearance of an intense type I difference spectrum. Very similar results were observed with two allelic forms of human liver P450 3A4, P450 NF25 and P450 hPCN1, produced in yeast. In both cases all the ergopeptides studied showed high affinities for the P450s (Ks 0.6-2.2 microM) and an intense shift from the low-spin to the high-spin state upon substrate binding (60-100% spin shift). Lysergic acid derivatives not bearing the tripeptide group of ergopeptides also completely failed to interact with P450s 3A4. Liver microsomes from rats pretreated with dexamethasone, a specific inducer of P450 3A, were found to be particularly active for the hydroxylation of bromocriptine, which occurs at the level of its tripeptide moiety. Human liver microsomes as well as P450 NF25 and P450 hPCN1 also exhibited a high activity for bromocriptine hydroxylation at this level. These results show that ergopeptides exhibit a particularly high affinity for P450s of the 3A subfamily. The tripeptide moiety of ergopeptides is essential for their recognition by P450s 3A and binds at a site close to P450 heme, producing type-I difference spectra. Accordingly, at least one of the studied ergopeptides, bromocriptine, is hydroxylated by P450s 3A at the proline ring of the cyclopeptide moiety. As cyclosporine is known to be a good substrate of P450s 3A, these results suggest that P450s 3A may be especially prone in a general manner to recognize and oxidize peptides or pseudopeptides.

[1]  D. Mansuy,et al.  Expression in yeast of three allelic cDNAs coding for human liver P-450 3A4. Different stabilities, binding properties and catalytic activities of the yeast-produced enzymes. , 1993, European journal of biochemistry.

[2]  P. Reisdorf,et al.  Enhanced in vivo monooxygenase activities of mammalian P450s in engineered yeast cells producing high levels of NADPH-P450 reductase and human cytochrome b5. , 1993, Gene.

[3]  E. Mini,et al.  Pharmacokinetic Drug Interactions of Macrolides , 1992, Clinical pharmacokinetics.

[4]  D. Mansuy,et al.  Optimization of yeast-expressed human liver cytochrome P450 3A4 catalytic activities by coexpressing NADPH-cytochrome P450 reductase and cytochrome b5. , 1992, European journal of biochemistry.

[5]  F. Guengerich,et al.  Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. , 1991, The Journal of pharmacology and experimental therapeutics.

[6]  D. Mansuy,et al.  Hydroxylation and formation of electrophilic metabolites of tienilic acid and its isomer by human liver microsomes. Catalysis by a cytochrome P450 IIC different from that responsible for mephenytoin hydroxylation. , 1991, Biochemical pharmacology.

[7]  M. Sari,et al.  Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. , 1990, Biochemistry.

[8]  T. Shimada,et al.  Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: comparison of those with rat hepatic cytochrome P-450s. , 1990, The Journal of pharmacology and experimental therapeutics.

[9]  P. Beaune,et al.  Expression of human liver cytochrome P450 IIIA4 in yeast. A functional model for the hepatic enzyme. , 1990, European journal of biochemistry.

[10]  C. Bonfils,et al.  Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[11]  S. Wrighton,et al.  Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). , 1990, Molecular pharmacology.

[12]  D. Pompon,et al.  Maximizing the expression of mammalian cytochrome P-450 monooxygenase activities in yeast cells. , 1990, Biochimie.

[13]  M. V. Nelson,et al.  Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine , 1990, Clinical pharmacology and therapeutics.

[14]  M. Delaforge,et al.  Metabolism of dihydroergotamine by a cytochrome P-450 similar to that involved in the metabolism of macrolide antibiotics. , 1989, Xenobiotica; the fate of foreign compounds in biological systems.

[15]  U. Meyer,et al.  Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4 , 1989, Clinical pharmacology and therapeutics.

[16]  T. Kronbach,et al.  Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. , 1989, Molecular pharmacology.

[17]  P. Srivastava,et al.  Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. , 1989, Biochemistry.

[18]  J. Derancourt,et al.  Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[19]  P. Srivastava,et al.  Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. , 1989, The Journal of biological chemistry.

[20]  K. Wüthrich,et al.  Secondary structure determination for alpha-neurotoxin from Dendroaspis polylepis polylepis based on sequence-specific 1H-nuclear-magnetic-resonance assignments. , 1988, European journal of biochemistry.

[21]  T. Kronbach,et al.  Cyclosporine metabolism in human liver: Identification of a cytochrome P‐450III gene family as the major cyclosporine‐metabolizing enzyme explains interactions of cyclosporine with other drugs , 1988, Clinical pharmacology and therapeutics.

[22]  D. Pompon,et al.  Synthesis of functional mouse cytochromes P-450 P1 and chimeric P-450 P3-1 in the yeast Saccharomyces cerevisiae. , 1988, Gene.

[23]  F. Guengerich.  Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. , 1988, Molecular pharmacology.

[24]  O. Mcbride,et al.  Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. , 1988, DNA.

[25]  P. Beaune,et al.  Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[26]  F. Guengerich,et al.  Oxidation of quinidine by human liver cytochrome P-450. , 1986, Molecular pharmacology.

[27]  D. Waxman,et al.  Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. , 1986, The Journal of biological chemistry.

[28]  P. Watkins,et al.  Identification of an inducible form of cytochrome P-450 in human liver. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. Delaforge,et al.  Dual effects of macrolide antibiotics on rat liver cytochrome P-450. Induction and formation of metabolite-complexes: a structure-activity relationship. , 1983, Biochemical pharmacology.

[30]  D. Pessayre,et al.  Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. , 1983, Biochemical pharmacology.

[31]  L. Guarente,et al.  A GAL10-CYC1 hybrid yeast promoter identifies the GAL4 regulatory region as an upstream site. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[32]  F. Guengerich,et al.  Purification and characterization of liver microsomal cytochromes p-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or beta-naphthoflavone. , 1982, Biochemistry.

[33]  L. Pershing,et al.  Cytochrome P-450 metabolic-intermediate complex formation and induction by macrolide antibiotics; a new class of agents. , 1982, Xenobiotica; the fate of foreign compounds in biological systems.

[34]  D. Pessayre,et al.  Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans. , 1982, Biochemical pharmacology.

[35]  P. Beaune,et al.  Cytochrome P-450 monooxygenase activities in human and rat liver microsomes. , 1981, European journal of biochemistry.

[36]  D. Pessayre,et al.  Self-induction by triacetyloleandomycin of its own transformation into a metabolite forming a stable 456 nm-absorbing complex with cytochrome P-450. , 1981, Biochemical pharmacology.

[37]  J. Peterson.  Camphor binding by Pseudomonas putida cytochrome P-450 , 1971 .

[38]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.

[39]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[40]  P. Hanzlik.  ON THE RECOVERY OF ALCOHOL FROM ANIMAL TISSUES , 1912 .

[41]  P. Beaune,et al.  Engineered yeast cells as model to study coupling between human xenobiotic metabolizing enzymes. Simulation of the two first steps of benzo[a]pyrene activation. , 1993, European journal of biochemistry.

[42]  M. J. Coon,et al.  The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. , 1993, DNA and cell biology.

[43]  G. Luisi,et al.  Approaches to pseudopeptidic ergopeptines. Synthesis and molecular structure of an α-aza-phenylalanine-containing oxa-cyclol , 1993 .

[44]  J. Hoogmartens,et al.  Macrolides, chemistry, pharmacology and clinical uses , 1993 .

[45]  A. Vickers,et al.  Characterization of the cytochrome P-450 gene family responsible for the N-dealkylation of the ergot alkaloid CQA 206-291 in humans. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[46]  F. Gonzalez,et al.  Human cytochromes P450: problems and prospects. , 1992, Trends in pharmacological sciences.

[47]  F. Guengerich,et al.  Expression of mammalian cytochrome P450 enzymes using yeast-based vectors. , 1991, Methods in enzymology.

[48]  T. Ludden.  Pharmacokinetic Interactions of the Macrolide Antibiotics , 1985, Clinical pharmacokinetics.

[49]  P. Strittmatter,et al.  [8] Purification of cytochrome b5 , 1978 .

[50]  Hayton Ac.  Precipitation of acute ergotism by triacetyloleandomycin. , 1969 .